BioAge Fell 64%. Its Drug Had Not Failed.

Novo Nordisk's inflammation drug lowered hsCRP but did not reduce heart attacks or strokes. BioAge was punished because its Phase 2 trial also uses hsCRP. This free briefing explains what the result changed, what it did not, and what evidence matters next.

Free to join. After signup, you can explore Premium free for seven days, then $33/month. No card required.

Built for self-directed biotech and healthcare investors who want disciplined company analysis, not stock tips.